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ABSTRACT
Introduction. AZD4877 is a potent Eg5 inhibitor that has been shown to have an acceptable tolerability proﬁle in
a Phase I study of Western patients with solid tumors. This study was conducted to evaluate the safety, pharmaco-
kinetic (PK) proﬁle, maximum tolerated dose (MTD) and efﬁcacy of AZD4877 in a Japanese population with solid
tumors.
Methods. In this Phase I, open-label, dose-escalation study, AZD4877 (10, 15, 20 or 25 mg) was administered as a
1-hour intravenous infusion on days 1, 8 and 15 of repeated 28-day cycles to Japanese patients with advanced solid
tumors. Adverse events (AEs) were evaluated according to Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0. PK variables were assessed pre- and post dosing. The MTD of AZD4877 was determined by
evaluating dose-limiting toxicities (DLTs). Efﬁcacy was evaluated by assessing best response according to Response
Evaluation Criteria In Solid Tumors version 1.0.
Results. Of the 21 patients enrolled, 18 received at least one dose of AZD4877 (N = 3 in both the 10 and 15 mg
cohorts, N = 6 in both the 20 and 25 mg cohorts). The most commonly reported AEs were fatigue and nausea (39%
of patients each). One patient in each of the 20 and 25 mg cohorts experienced a DLT (neutropenia and febrile
neutropenia). Dose escalation was halted at 25 mg and the MTD was not deﬁned in this population. CTCAE grade
3 abnormal laboratory ﬁndings/vital signs were reported in 12 patients, with neutropenia (56%) and leukopenia
(44%) being the most commonly reported. Exposure to AZD4877 was not fully dose proportional and AZD4877
clearance and elimination half-life appeared independent of dose. The best response to AZD4877 was stable disease
in ﬁve of 16 evaluable patients.
Conclusion. AZD4877 up to doses of 25 mg was well tolerated in Japanese patients. There was little evidence of
clinical efﬁcacy.
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Introduction
K
inesin spindle protein, also known as Eg5,
is a microtubule motor protein essential for
the formation of a bipolar mitotic spindle and
Study type: Open label, dose escalation
Study phase: Phase I
Study registration number: ClinicalTrials.gov,
NCT00613652
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Eg5 expression is elevated in several proliferative
tissues, including the thymus, tonsil, testis, esoph-
ageal epithelium and bone marrow, as well as in
a number of solid tumors and leukemias [2–4].
Inhibition of Eg5 in replicating cells has been
shown to prevent centrosomal separation and
mitotic spindle assembly, which leads to the for-
mation of monopolar spindles (“monoasters”),
activation of the spindle checkpoint and mitotic
arrest, resulting in cell death [1,5,6].
First generation antimitotic drugs, such as the
taxanes and vinca alkaloids, have been shown to be
effective anticancer agents [7]. However, by target-
ing tubulin, these agents affect the microtubular
architecture of non-proliferating cells, which leads
to a high incidence of neurotoxic side effects
as well as myelosuppression [8,9]. Eg5 is not
expressed in non-proliferating cells or in the adult
peripheral nervous system, and so inhibition of
Eg5 only targets actively mitotic cells [10]. There-
fore, Eg5 inhibitors are not expected to cause the
neurotoxic side effects commonly observed with
traditional antimitotic agents [2,11]. Inhibition
of Eg5 has been shown to cause cell death in a
number of preclinical cancer cell lines and to
have antiproliferative activity in human tumor
xenograft models [11–15].
AZD4877 is a potent inhibitor of Eg5 that pre-
vents centrosome separation and mitotic spindle
assembly resulting in mitotic arrest, induction of
apoptosis and cell death. AZD4877 was shown to
inhibit growth of a broad panel of solid and hema-
tologic tumor cell lines [16]. Furthermore, activity
was observed in human tumor xenograft models
including a primary bladder tumor model and the
rituximab-insensitive non-Hodgkin’s lymphoma
model, DoHH2T53. In a Phase I study in Western
patients, AZD4877 25 mg was shown to have an
acceptable tolerability proﬁle with evidence of
monoaster formation suggesting proof of mecha-
nism in a clinical setting. The best objective tumor
response to AZD4877 was only stable disease [17].
The aim of this Phase I study was to evaluate
the safety, pharmacokinetic (PK) proﬁle, maxi-
mum tolerated dose (MTD) and efﬁcacy of
AZD4877 in Japanese patients with solid tumors.
Methods
Patients
Patients with advanced solid malignancies aged
20–75 years were included if they had a histologi-
cally or cytologically conﬁrmed solid malignancy
for which no standard curative or palliative mea-
sures existed or were no longer effective, and a
World Health Organization (WHO) performance
status of 0 or 1. Patients who had received prior
treatment with an anticancer agent within 28 days
of the ﬁrst dose of study treatment (6 weeks for
mitomycin treatment) were excluded from the
study. Other exclusion criteria included absolute
neutrophil count <1.5 ¥ 10
9/L, platelet count
<100 ¥ 10
9/L, hemoglobin 9 g/dL, inadequate
renal function (creatinine >1.3 ¥ upper limit of
normal [ULN]) or liver function (serum bilirubin
>1.5 ¥ ULN) as well as evidence of severe or
uncontrolled systemic disease.
All patients provided written informed consent.
The study was approved by the independent ethics
committeeforthetrialcenterandwasconductedin
accordance with the Declaration of Helsinki [18].
Study Design
This was a Phase I, open-label, single-center,
dose-escalation study in Japanese patients
(ClinicalTrials.gov identiﬁer NCT00613652).
AZD4877 was administered at escalating doses in
separate cohorts of patients starting at 10 mg given
as a 1-hour intravenous (iv) infusion on days 1, 8
and 15 of a 28-day cycle (Figure 1). The next
Figure 1 Study design.
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based on assessment of dose-limiting toxicities
(DLTs). The MTD was identiﬁed as the highest
dose at which no more than one of six patients
experienced a DLT during cycle 1. Following
completion of cycle 1, patients could receive con-
secutive treatment with AZD4877 if they contin-
ued to beneﬁt and there was no evidence of disease
progression.
Objectives
The primary objectives of this study were to inves-
tigate the safety, tolerability and PK proﬁle of
AZD4877. The secondary objective was to evalu-
ate the MTD of AZD4877 based on assessment of
DLTs. Exploratory objectives included assessment
of the antitumor activity of AZD4877 and evalua-
tion of serum levels of the tumor cell death bio-
markers M30 (caspase-cleaved cytokeratin 18) and
M65 (cytokeratin 18).
Assessments
Safety and tolerability were evaluated by assess-
ment of adverse events (AEs) according to
Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0. Laboratory assess-
ments (clinical chemistry and hematology) were
undertaken using samples collected pre-dose and
on days 1, 8, 15 and 22 of cycles 1 and 2, and
urinalysis was undertaken using samples collected
pre-dose and on days 1, 8 and 15 of cycle 1 and on
day 1 of subsequent cycles.
The MTD of AZD4877 was deﬁned as the
highest dose at which no more than one of six
evaluable patients experienced a DLT during cycle
1. DLTs were deﬁned as grade 3 or 4 hemolysis,
grade 4 hematologic toxicity (thrombocytopenia
or neutropenia >4 days), grade 3 or 4 neutropenia
complicated by fever (oral temperature 38.5°C;
axillary temperature 38.0°C), grade 2 diarrhea
>4 days despite optimal management, grade 3 or 4
vomiting for >24 hours despite suitable anti-
emetics or other grade 3 or 4 non-hematologic
toxicity.
Blood samples for PK analysis were collected
daily at various timepoints pre- and post-dose on
days 1–8 of cycle 1, and day 1 of cycle 2. PK
parameters evaluated included maximum plasma
drug concentration (Cmax), plasma drug concentra-
tion24hoursafteradministration(C24h),areaunder
the concentration–time curve from zero to inﬁnity
(AUC0–•),areaundertheconcentration–timecurve
from zero to 24 hours (AUC0–24h), half-life associ-
ated with the terminal slope of a semi-logarithmic
concentration–time curve (t z 1
2λ ), mean residence
time (MRT), apparent volume of distribution
at steady state (Vss) and total apparent plasma
clearance (CL). Non-compartmental methods
were used for the evaluation of the plasma
concentration–time data and Cmax was determined
by inspection of the concentration–time proﬁles.
Where possible, the terminal elimination rate
constant(l)wascalculatedbylog–linearregression
of the terminal portion of the concentration–
time proﬁles, and t z 1
2λ was deﬁned as 0.6932/lZ.
AUC0–24hwasdeterminedusingthelineartrapezoi-
dal rule, and where appropriate, AUC0–24h was
extrapolated to inﬁnity using l to obtain AUC0–•
values. MRT was calculated as the ratio of the area
under the ﬁrst moment curve (AUMC) to AUC
plus the infusion duration/2. Total apparent clear-
ance was calculated from the ratio of dose/AUC
and Vss was determined from the MRT ¥ CL.
The methods for the PK parameter assessments
and calculations reported in this study have been
described previously [19].
The tumor cell death biomarkers M30 and
M65 have previously been shown to be elevated
in patients with a variety of cancers and are
considered to be measures of apoptosis and
tumor burden. Blood samples for M30 and M65
biomarker assessment were taken pre-dose and at
24, 48, 72, 96 and 120 hours after infusion and
on day 8 of cycle 1. Serum was extracted from
whole blood samples (3 mL) by centrifugation
(1,000 ¥ g at 4°C) and stored at -20°C until
required. Biomarker analysis was performed in
duplicate by the Experimental Pharmacology
Group, Paterson Institute of Cancer Research,
University of Manchester (UK). Baseline cor-
rected values were calculated by subtracting the
mean of the two pre-dose values from the post-
dose values.
Efﬁcacy was determined by investigator assess-
ment of overall best response according to
Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.0. Baseline radiologic tumor
assessments were performed within 28 days prior
to administration of the ﬁrst dose, and subsequent
tumor evaluations were performed on day 29 of
cycles 1 and 2 and subsequent odd numbered
cycles. The minimum period of stable disease was
deﬁned as 8 weeks.
Statistical Analysis
Data are summarized descriptively by dose group.
Due to the limited number of patients expected in
each dose group (N = 3–6 per group), no formal
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Results
Patient Characteristics
A total of 21 patients were enrolled in this study
during January 2008 to June 2009. Of the 21
patients, 18 received at least one dose of AZD4877
ranging from doses of 10 to 25 mg (Table 1). The
mean age of patients was 62.7 years and 11
(61.1%) were female. All patients had advanced
solid malignancies with a broad representation of
primary tumor types, of which lung (33.3%) and
breast cancer (16.7%) were the most common.
Seventeen of 18 patients discontinued study
treatment due to lack of therapeutic response and
one patient in the 20 mg dose cohort withdrew
from the study due to an AE (grade 2 cystitis).
The median duration of treatment across all
doses of AZD4877 was 50 days (range 15–163),
with the longest median duration of 100 days
(range 45–133) being in the 10 mg dose cohort.
The median number of treatment cycles initiated
across all doses was 2 (range 1–6). Of the 18
patients treated with AZD4877, only seven were
continuing to receive their fully assigned dose by
day 1 of cycle 2.
Safety
All patients experienced at least one AE, of which
the most commonly reported were fatigue (39%),
nausea (39%), and pyrexia (33%) (Table 2). The
majority of these were mild or moderate in inten-
sity (CTCAE grade 1 or 2). Three patients expe-
rienced CTCAE grade 3 events; one in the
20 mg dose cohort experienced grade 4 neutrope-
nia and two in the 25 mg dose cohort experienced
grade 4 febrile neutropenia and grade 3 constipa-
tion, fatigue, urinary tract infection and anorexia,
respectively (Table 3a). There were no deaths
during the study.
Two patients in the 20 and 25 mg cohorts expe-
rienced DLTs; CTCAE grade 4 neutropenia and
febrile neutropenia, respectively. Grade 3 consti-
pation, fatigue, urinary tract infection and anor-
exia were not considered to be DLTs because
they occurred 1 week after the completion of
cycle 1 and were not considered causally related to
Table 1 Patient demographics and baseline characteristics
AZD4877 dose
†
10 mg (N = 3) 15 mg (N = 3) 20 mg (N = 6) 25 mg (N = 6) Total (N = 18)
Age (years)
Mean (SD) 66.7 (4.0) 62.7 (5.5) 62.2 (10.7) 61.3 (9.6) 62.7 (8.4)
Range 63–71 59–69 45–73 50–75 45–75
Gender, N (%)
Male 2 (67) 2 (67) 1 (17) 2 (33) 7 (39)
Female 1 (33) 1 (33) 5 (83) 4 (67) 11 (61)
WHO performance status, N (%)
Normal activity (0) 1 (33) 3 (100) 2 (33) 2 (33) 8 (44)
Restricted activity (1) 2 (67) 0 4 (67) 4 (67) 10 (56)
Primary tumor site, N (%)
Lung 1 (33) 0 3 (50) 2 (33) 6 (33)
Breast 0 1 (33) 0 2 (33) 3 (17)
Pleura/pleural effusion 0 0 1 (17) 0 1 (6)
Prostate 0 1 (33) 0 0 1 (6)
Stomach 0 0 1 (17) 0 1 (6)
Colon 1 (33) 0 0 0 1 (6)
Other
‡ 1 (33) 1 (33) 1 (17) 2 (33) 5 (28)
†Dose assigned on day 1 of cycle 1.
‡Other tumor sites include: thymus (2), ureter (1), renal/prostate (1) and primary unknown tumor (1).
SD = standard deviation; WHO = World Health Organization.
Table 2 CTCAE of any grade reported in 20% of
patients overall
Patients with AEs, N (%)
AZD4877 dose
10 mg
(N = 3)
15 mg
(N = 3)
20 mg
(N = 6)
25 mg
(N = 6)
Total
(N = 18)
Fatigue 1 (33) 1 (33) 2 (33) 3 (50) 7 (39)
Nausea 2 (67) 1 (33) 1 (17) 3 (50) 7 (39)
Pyrexia 0 3 (100) 2 (33) 1 (17) 6 (33)
Diarrhea 2 (67) 1 (33) 0 2 (33) 5 (28)
Dizziness 2 (67) 0 3 (50) 0 5 (28)
Rash 0 3 (100) 2 (33) 0 5 (28)
Constipation 1 (33) 0 1 (17) 2 (33) 4 (22)
Nasopharyngitis 0 0 2 (33) 2 (33) 4 (22)
Insomnia 1 (33) 0 2 (33) 1 (17) 4 (22)
26 Esaki et al.
Arch Drug Info 2011;4:23–31treatment by the investigator. The 20 and 25 mg
dose cohorts were therefore expanded to six
patients, however, no further DLTs were observed.
Twelve patients experienced CTCAE grade 3
abnormal laboratory ﬁndings/vital signs, the most
common of which were neutropenia (56%) and
leukopenia (44%). The incidence of neutropenia
increased in an approximately dose-proportional
manner, with ﬁve of six patients in the 25 mg dose
cohort experiencing grade 3 neutropenia
(Table 3b). Overall, the nadir in the laboratory
hematology variables of white blood cell count,
platelet count and absolute neutrophil count
occurred by day 15 of cycle 1 (Table 3c). There
were no other clinically relevant changes or trends
in laboratory parameters or vital signs (WHO per-
formance status, physical ﬁndings or ECG obser-
vations) over the dosing range.
Pharmacokinetics
Systemic exposure to AZD4877 (as calculated by
Cmax, AUC0–•,C 24h and AUC0–24h) increased in an
approximately dose-proportional manner in the 10
and 15 mg cohorts, however, greater than dose-
proportional increases were observed between the
10 and 20 mg cohorts and little change was
Table 3a CTCAE grade 3 events reported by any patient
Patients with grade 3 event, N (%)
AZD4877 dose
10 mg
(N = 3)
15 mg
(N = 3)
20 mg
(N = 6)
25 mg
(N = 6)
Total
(N = 18)
Any grade 3 event 0 0 1 (17) 2 (33) 3 (17)
Febrile neutropenia 0 0 0 1 (17) 1 (6)
Neutropenia 0 0 1 (17) 0 1 (6)
Constipation 0 0 0 1 (17) 1 (6)
Fatigue 0 0 0 1 (17) 1 (6)
Urinary tract
infection
0 0 0 1 (17) 1 (6)
Anorexia 0 0 0 1 (17) 1 (6)
Table 3b CTCAE grade 3 abnormal laboratory ﬁndings/vital signs reported by any patient
Patients with grade 3 abnormal laboratory ﬁndings/vital signs, N (%)
AZD4877 dose
10 mg (N = 3) 15 mg (N = 3) 20 mg (N = 6) 25 mg (N = 6) Total (N = 18)
Any grade 3 ﬁnding/vital sign 1 (33) 1 (33) 4 (67) 6 (100) 12 (67)
Neutropenia 1 (33) 1 (33) 3 (50) 5 (83) 10 (56)
Leukopenia 0 0 3 (50) 5 (83) 8 (44)
Lymphopenia 0 0 0 1 (17) 1 (6)
Thrombocytopenia 0 0 0 1 (17) 1 (6)
Blood sodium decreased 0 0 1 (17) 0 1 (6)
Hemoglobin decreased 0 0 0 1 (17) 1 (6)
Lymphocyte count decreased 0 0 0 1 (17) 1 (6)
Weight decreased 0 0 1 (17) 0 1 (6)
Cut-off value for values for deﬁning grade 3 abnormal laboratory ﬁnding: neutropenia <1.0 ¥ 109/L; leukopenia <2.0 ¥ 109/L; lymphopenia: <0.5 ¥ 109/L;
thrombocytopenia: <50.0 ¥ 109/L; blood sodium decreased: <130 mmol/L; hemoglobin decreased: <8.0 g/dL; lymphocyte count decreased: <0.5 ¥ 109/L; weight
decreased: 20% from baseline.
Table 3c Selected laboratory hematology variables at baseline and during cycle 1
Parameter, mean (SD)
AZD4877 dose
10 mg (N = 3) 15 mg (N = 3) 20 mg (N = 6) 25 mg (N = 6) Total (N = 18)
White blood cell count, 10
3/mL
Baseline 4.28 (0.91) 6.95 (1.46) 6.03 (3.08) 4.94 (1.28) 5.53 (2.11)
Cycle 1, Day 8 4.13 (0.63) 5.50 (1.48) 2.97 (1.06) 3.01 (0.99) 3.60 (1.37)
Cycle 1, Day 15 3.59 (0.69) 4.66 (2.19) 2.82 (1.20) 1.58 (0.57) 2.84 (1.55)
Cycle 1, Day 22 4.09 (0.66) 4.53 (1.70) 2.64 (0.69) 2.73 (0.68) 3.23 (1.14)
Platelet count, 10
3/mL
Baseline 233.3 (69.3) 242.3 (21.5) 279.2 (40.2) 276.5 (71.7) 264.5 (54.7)
Cycle 1, Day 8 227.3 (36.7) 229.0 (35.9) 245.7 (45.5) 246.5 (99.7) 240.1 (62.6)
Cycle 1, Day 15 203.3 (46.5) 217.0 (6.1) 265.2 (79.5) 184.5 (85.1) 219.9 (73.9)
Cycle 1, Day 22 205.0 (54.0) 232.0 (7.9) 262.2 (48.0) 308.7 (117.3) 263.1 (81.1)
Total ANC, 10
3/mL
Baseline 2.48 (0.38) 4.36 (0.87) 4.34 (2.95) 3.39 (1.38) 3.72 (1.94)
Cycle 1, Day 8 2.00 (0.37) 3.23 (1.26) 1.81 (0.99) 2.00 (0.97) 2.14 (1.01)
Cycle 1, Day 15 1.25 (0.27) 2.33 (1.62) 1.49 (0.82) 0.57 (0.50) 1.28 (0.99)
Cycle 1, Day 22 1.68 (0.35) 2.30 (1.50) 1.25 (0.69) 1.41 (0.48) 1.55 (0.79)
ANC = absolute neutrophil count.
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(Figure 2). MRT, t z 1
2λ and VSS values remained
relatively unchanged in the 15, 20 and 25 mg
cohorts, however, higher values for each of these
parameters were reported in the 10 mg cohort
(Table 4). Clearance of AZD4877 was similar in
the 10, 15 and 25 mg cohorts (19.5 to 22.4 L/h)
but lower in the 20 mg cohort (14.0 L/h).
Biomarkers
Overall, there was an approximately 15% mean
decrease from baseline in the tumor cell death
biomarkers, M30 and M65 in the 15, 20 and 25 mg
dose cohorts over the 8-day assessment period of
cycle 1. Consistent with this ﬁnding, peaks in these
biomarkers were observed in the 20 and 25 mg
dose cohorts on days 1 and 2, potentially indicat-
ing waves of drug-induced cell death at the earlier
timepoints. A different proﬁle was observed for the
10 mg dose with no reduction in levels of M30 or
M65 by day 8. Mean percentage changes from
baseline for M30 and M65 values within the ﬁrst 8
days of therapy are shown in Figure 3. In the
AZD4877 20 and 25 mg cohorts, decreases in both
biomarkers were observed from days 3 to 8. Fur-
thermore, changes from baseline of >30% were
observed for several patients over the 8-day assess-
ment period (Figure 4).
Figure 2 Geometric mean plasma
concentration of AZD4877 versus time
by dose level following single dosing.
SD = standard deviation.
Table 4 Pharmacokinetic parameters of AZD4877 during cycle 1
PK parameter
AZD4877 dose
10 mg (N = 3) 15 mg (N = 3) 20 mg (N = 6) 25 mg (N = 6)
Cmax (ng/mL) 63.4 (22.4) 99.7 (59.0) 218.0 (51.2) 224.0 (15.8)
C24h (ng/mL) 4.9 (13.4) 7.8 (55.3) 14.9 (38.9) 13.6 (47.8)
AUC0–• (ng·h/mL) 447.0 (20.0) 671.0 (60.5) 1430.0 (33.5) 1280.0 (19.4)
AUC0–24h (ng·h/mL) 234.0 (17.6) 424.0 (45.3) 882.0 (32.3) 838.0 (15.9)
t z 1
2λ (h) 28.7 (9.0) 20.3 (32.5) 21.3 (45.9) 21.1 (27.7)
MRT (h) 34.2 (8.9) 22.9 (36.3) 22.4 (59.7) 22.2 (26.1)
VSS (L) 766.0 (11.6) 512.0 (37.3) 314.0 (52.3) 432.0 (24.6)
CL (L/h) 22.4 (20.0) 22.3 (60.5) 14.0 (33.5) 19.5 (19.4)
Data are expressed as geometric mean (CV%).
AUC0–• = area under the plasma concentration–time curve from zero to inﬁnity;AUC0–24h = area under the plasma concentration–time curve from zero to 24 hours;
C24h = plasma drug concentration 24 hours after administration; CL = total body clearance of drug from plasma; Cmax = maximum plasma drug concentration;
CV = coefficient of variation; MRT = mean residence time; SD = standard deviation; t z 1
2λ = half-life associated with the terminal slope (lz) of a semi-logarithmic
concentration–time curve; VSS = volume of distribution at steady state.
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No patients experienced a complete or partial
response. The overall best response was stable
disease 8 weeks, which was observed in ﬁve of 16
evaluable patients; two in the 10 mg cohort (one
lung and one ureter cancer), one in the 15 mg
cohort (renal/prostate cancer) and two in the
20 mg cohort (one lung and one thymus). The
patient in the 20 mg cohort with thymus cancer
had stable disease for 12 weeks.
Discussion
AZD4877 monotherapy at doses up to 25 mg
weekly was generally well tolerated in Japanese
patients with a range of solid tumors. The most
commonly reported CTCAE grade 3 abnormal
laboratory ﬁndings/vital signs was neutropenia,
which was dose related. Two patients in the 20
and 25 mg cohorts experienced DLTs, of grade 4
neutropenia and febrile neutropenia, however,
there were no more DLTs when the cohorts were
expanded. In a parallel US study, patients with
solid tumors receiving AZD4877 30 mg experi-
enced neutropenia, which led to 25 mg being
deﬁned as the recommended dose for further
evaluation [17]. Consequently, the MTD for
AZD4877 was not deﬁned in Japanese patients.
Systemic exposure to AZD4877 was not fully
dose proportional, which may be due to the small
Figure 3 Mean change from baseline (%) in (A) M30 and (B) M65 values within the ﬁrst 8 days of cycle 1.
Figure 4 Change (%) in (A) M30 and (B) M65 from baseline on day 1 to day 8 for individual patients.
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the PK parameters for AZD4877 in Japanese
patients were comparable with those reported in
Western patients [17]. Although reductions in the
levels of the tumor cell death biomarkers M30 and
M65, possibly due to a small reduction in tumor
burden, were noted within the ﬁrst 8 days of
therapy the best response to AZD4877 was stable
disease 8 weeks. Similarly, the best response to
weekly treatment with AZD4877 in Western
patients was also stable disease 12 weeks [17].
This limited clinical response is similar to that
reported for other Eg5 inhibitors [20–25], and
may be due to an insufﬁcient therapeutic window
or drug-resistant Eg5 mutations.
In conclusion, treatment with AZD4877 is fea-
sible in Japanese patients with advanced solid
tumors. The best objective tumor response to
AZD4877 was only stable disease. Because of the
relative lack of clinical efﬁcacy in this and other
completed Phase I and II trials of AZD4877,
further development of this agent is not planned.
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